CCR2 and metabolic disease: Various other CCR2, CCL2, or CCR2/CCR5 inhibitors are currently developed and tested in other inflammatory/metabolic diseases (e.g., type 2 diabetes), clinical trials are needed though to define their efficacy in liver diseases (128).